Sight Sciences Inc. (SGHT)
NASDAQ: SGHT
· Real-Time Price · USD
3.69
-0.04 (-1.07%)
At close: Sep 05, 2025, 3:59 PM
3.69
0.00%
After-hours: Sep 05, 2025, 04:10 PM EDT
Sight Sciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Eye Revenue | 333K | 394K | 305K | 1.52M | 1.13M | 1.01M | 2.54M | 1.58M | 1.14M | 1.49M | 1.79M | 1.6M | 1.33M | 1.01M | 762K | 655K | 547K |
| Dry Eye Revenue Growth | -15.48% | +29.18% | -80.00% | +35.44% | +11.71% | -60.25% | +60.10% | +39.44% | -23.76% | -16.81% | +11.59% | +20.68% | +31.55% | +32.68% | +16.34% | +19.74% | n/a |
| Surgical Glaucoma Revenue | 19.23M | 17.11M | 18.77M | 18.63M | 20.24M | 18.26M | 17.15M | 18.43M | 21.4M | 17.33M | 18.75M | 17.07M | 15.9M | 13.87M | 13.92M | 12.45M | 11.99M |
| Surgical Glaucoma Revenue Growth | +12.37% | -8.82% | +0.74% | -7.96% | +10.88% | +6.44% | -6.90% | -13.89% | +23.45% | -7.56% | +9.84% | +7.38% | +14.63% | -0.38% | +11.87% | +3.82% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 23.87M | 24.52M | 24.2M | 23.39M | 26.68M | 26.56M | 23.66M | 26.5M | 30.06M | 28.68M | 28.7M | 31.54M | 31.43M | 28.39M | 23.09M | 20.79M | 17.76M | 14.55M | 12.18M | 11.23M | 7.66M | 10.68M |
| Selling, General, and Administrative Revenue Growth | -2.68% | +1.35% | +3.45% | -12.33% | +0.46% | +12.26% | -10.74% | -11.82% | +4.82% | -0.08% | -9.01% | +0.35% | +10.69% | +22.98% | +11.06% | +17.06% | +22.06% | +19.51% | +8.43% | +46.50% | -28.23% | n/a |
| Research and Development Revenue | 4.39M | 4.43M | 4.29M | 4.75M | 4.32M | 4.64M | 3.43M | 4.24M | 5.22M | 4.67M | 5.23M | 6.05M | 5.93M | 5.65M | 4.37M | 4.28M | 3.55M | 3.44M | 2.87M | 2.16M | 1.44M | 2.4M |
| Research and Development Revenue Growth | -0.97% | +3.19% | -9.54% | +9.96% | -6.90% | +35.28% | -19.16% | -18.81% | +11.82% | -10.78% | -13.55% | +2.14% | +4.96% | +29.23% | +2.10% | +20.67% | +3.08% | +19.74% | +33.13% | +49.55% | -39.88% | n/a |